Alluvi, initially dubbed LY3414901, represents a significant advancement in obesity management. This dual -action glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor https://alluviretatrutide887201.azzablog.com/43471402/alluvi-a-detailed-exploration-into-the-medication-s-promise